Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.

@article{Bianchi2009PhaseIM,
  title={Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.},
  author={Giulia Valeria Bianchi and Sibylle Loibl and Claudio Zamagni and Stefania Salvagni and Guenter Raab and Salvatore Siena and Nicole Laferriere and Carol E Pe{\~n}a and Chetan Lathia and Loredana Bergamini and Luca Gianni},
  journal={Anti-cancer drugs},
  year={2009},
  volume={20 7},
  pages={
          616-24
        }
}
  • Giulia Valeria Bianchi, Sibylle Loibl, +8 authors Luca Gianni
  • Published in Anti-cancer drugs 2009
  • Medicine
  • This trial was conducted to assess the efficacy and safety of sorafenib in patients with metastatic breast cancer. In this multinational, open-label phase II study, patients with metastatic breast cancer that had progressed after at least one prior chemotherapy regimen were continuously treated with oral sorafenib, 400 mg twice daily. The primary endpoint was overall best response; a secondary endpoint was percentage of patients with stable disease for greater than or equal to 16 weeks… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 58 CITATIONS, ESTIMATED 43% COVERAGE

    Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment

    • Ying Lin, Zheng Wu, +5 authors Leiping Wang
    • Biology, Medicine
    • Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
    • 2017

    FILTER CITATIONS BY YEAR

    2007
    2019

    CITATION STATISTICS

    • 1 Highly Influenced Citations

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 38 REFERENCES

    Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.